GTx GTXI announced Thursday that the Data Safety Monitoring Board has ..... drug's composition of matter patent may expire around the time GTx expects an FDA approval in 2009. After that, GTx may need to rely on weak patents for market exclusivity.
We are raising GTx 's fair value on recent positive Phase II trial results for Ostarine.
GTx adds a European partner.
(Reuters) - GTx Inc's experimental drug to treat muscle wasting in cancer patients became its second successive lead drug to fail late-stage trials, wiping out nearly two-thirds of the market value...
We're dropping coverage of GTx Inc GTXI to focus our resources elsewhere.
GTx Inc. GTXI reported second-quarter results that came ..... treatment for advanced prostate cancer, GTx -758, met endpoints in a Phase II study ..... Administration, and will continue to push ahead on GTx 758. In the meantime, GTx continues to
GTx GTXI reported disappointing results in its Phase III trial for Acapodene for the ..... study protocol and demands a larger or more expensive trial that rises above GTx and partner Ipsen's preset funding threshold for a second trial . Then the
GTx GTXI announced Tuesday that it has expanded its deal with European partner Ipsen . Ipsen will pay GTx about $ 58 million in milestones for a second ..... European approval . This deal will improve GTx 's near - term cash reserves and help it
We are placing GTx GTXI under review until the firm reports earnings ..... of the Ostarine (MK-2866) compound. GTx partnered with Merck MRK on this compound ..... currently discussing next steps with GTx ." Ostarine drives the lion's share
GTx GTXI will report fourth-quarter results soon ..... Administration's complete response letter in November, GTx stated it planned to meet with the agency ..... scenario. We are also interested in whether GTx can use data from its prostate cancer prevention